Longitudinal Study of Body Composition of 101 HIV Men With Lipodystrophy: Dual-Energy X-Ray Criteria for Lipodystrophy Evolution

Journal of Clinical Densitometry

Volumn 13, Issue 2, 2010, Pages 237-244

  Degris, Emilie ^a   Delpierre, Cyrille ^b   Sommet, Agnès ^c   Sire, Stèphane ^d   Lassoued, Slim ^d   Aquilina, Christian ^e   Marchou, Bruno ^c   Massip, Patrice ^c   Obadia, Martine ^c   Marion Latard, Fabrice ^f   Bonnet, Eric ^c   Bernard, Jacques ^f  

^a Paul Sabatier University   (France)

^b INSERM   (France)

^c CHU PURPAN   (France)

^d Cahors Hospital   (France)

^e Serv Univ Psychiat l'Enfant l'A   (France)

^f CHU RANGUEIL   (France)

Author keywords

Antiretroviral therapy; body composition; bone mineral density; DXA assessment; HIV infected

Indexed keywords

ABACAVIR; EFAVIRENZ; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ANTIRETROVIRUS AGENT;

ABDOMINAL FAT; ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; BODY FAT DISTRIBUTION; BODY MASS; BONE DENSITY; CONTROLLED STUDY; DISEASE EXACERBATION; DUAL ENERGY X RAY ABSORPTIOMETRY; EARLY INTERVENTION; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEAN BODY WEIGHT; LEG; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VIRUS LOAD; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; METABOLISM; MIDDLE AGED; PHOTON ABSORPTIOMETRY; TREATMENT OUTCOME;

ABSORPTIOMETRY, PHOTON; ADULT; ANTI-RETROVIRAL AGENTS; BODY COMPOSITION; BODY MASS INDEX; BONE DENSITY; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77951621288     PISSN: 10946950     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocd.2009.12.004     Document Type: Article

References (41)

1. Bonnet E., Delpierre C., Sommet A., et al. Total body composition by DXA of 241 HIV-negative men and 162 HIV-infected men: proposal of reference values for defining lipodystrophy. J Clin Densitom 8 3 (2005) 287-292
2. Cavalcanti R.B., Cheung A.M., Raboud J., and Walmsley S. Reproducibility of DXA estimations of body fat in HIV lipodystrophy: implications for clinical research. J Clin Densitom 8 3 (2005) 293-297
3. Carr A., Samaras K., Burton S., et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12 7 (1998) F51-F58
4. Miller K.D., Jones E., Yanovski J.A., et al. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 351 9106 (1998) 871-875
5. Saves M., Raffi F., Capeau J., et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 34 10 (2002) 1396-1405
6. Mallal S.A., John M., Moore C.B., et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 14 10 (2000) 1309-1316
7. Carr A. HIV protease inhibitor-related lipodystrophy syndrome. Clin Infect Dis 30 Suppl 2 (2000) S135-S142
8. Saint-Marc T., Partisani M., Poizot-Martin I., et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 13 13 (1999) 1659-1667
9. Carr A., Workman C., Smith D.E., et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 288 2 (2002) 207-215
10. Martin A., Smith D.E., Carr A., et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 18 7 (2004) 1029-1036
11. Moyle G.J., Sabin C.A., Cartledge J., et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 20 16 (2006) 2043-2050
12. Madruga J.R., Cassetti I., Suleiman J.M., et al. The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapy. HIV Clin Trials 8 6 (2007) 381-390
13. Hansen A.B., Lindegaard B., Obel N., et al. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population. HIV Med 7 1 (2006) 38-45
14. Lafeuillade A., Clumeck N., Mallolas J., et al. Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir versus continued HAART: the Trizal study. HIV Clin Trials 4 1 (2003) 37-43
15. Jacobson D.L., Knox T., Spiegelman D., et al. Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. Clin Infect Dis 40 12 (2005) 1837-1845
16. Bergersen B.M., Sandvik L., Ellingsen I., and Bruun J.N. Lipoatrophic men 44 months after the diagnosis of lipoatrophy are less lipoatrophic but more hypertensive. HIV Med 6 4 (2005) 260-267
17. Moyle G. [Poster 938]. CROI. 2008.
18. Martinez E. International AIDS Conference [MOPDB 102]. Mexico 2008.
19. Bacchetti P., Gripshover B., Grunfeld C., et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 40 2 (2005) 121-131
20. Saint-Marc T., Partisani M., Poizot-Martin I., et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 14 1 (2000) 37-49
21. Galli M., Cozzi-Lepri A., Ridolfo A.L., et al. Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study. Arch Intern Med 162 22 (2002) 2621-2628
22. Young J., Rickenbach M., Weber R., et al. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study. Antivir Ther 10 1 (2005) 73-81
23. Tavassoli N., Bagheri H., Sommet A., et al. Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry. Pharmacotherapy 26 2 (2006) 154-161
24. Cameron D.W., da Silva B.A., Arribas J.R., et al. A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis 198 2 (2008) 234-240
25. Valantin M., Lanoy E., Bentata M., et al. Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial. HIV Med 9 8 (2008) 625-635
26. Cameron D.W., Becker S., King M.S., et al. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen. J Antimicrob Chemother 59 5 (2007) 957-963
27. Fernandez-Rivera J., Garcia R., Lozano F., et al. Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients. HIV Clin Trials 4 5 (2003) 337-346
28. Madeddu G., Spanu A., Solinas P., et al. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging 48 1 (2004) 39-48
29. Seminari E., Castagna A., Soldarini A., et al. Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. HIV Med 6 3 (2005) 145-150
30. Cazanave C., Dupon M., Lavignolle-Aurillac V., et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS 22 3 (2008) 395-402
31. Brown T.T., and Qaqish R.B. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 20 17 (2006) 2165-2174
32. Bruera D., Luna N., David D.O., et al. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 17 13 (2003) 1917-1923
33. Amiel C., Ostertag A., Slama L., et al. BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res 19 3 (2004) 402-409
34. Bolland M.J., Grey A.B., Horne A.M., et al. Bone mineral density is not reduced in HIV-infected Caucasian men treated with highly active antiretroviral therapy. Clin Endocrinol (Oxf) 65 2 (2006) 191-197
35. Singh K., and Moyle G.J. Bone mineral abnormalities in persons with HIV infection: signal or noise?. AIDS Read 16 8 (2006) 407-410 413-418
36. Bolland M.J., Grey A.B., Horne A.M., et al. Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years. Clin Endocrinol (Oxf) 67 2 (2007) 270-275
37. Bonnet E, Mabile L, Ruidavets JB, et al. Important changes in bone metabolism soon after commencing HAART. [Poster] 9th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Sydney; 2007.
38. Duvivier C, Kolta S, Assoumou L, et al. First-line PI-containing regimens enhance decreased bone mineral density greater than NNRTI-containing regimen in HIV-1 infected patients: a substudy of the HIPPOCAMPE-ANRS 121 trial. [Abstract] Proceedings of the 15th Conference on Retroviruses and Opportunistic Infections. Boston; 2008.
39. Huang J.S., Rietschel P., Hadigan C.M., et al. Increased abdominal visceral fat is associated with reduced bone density in HIV-infected men with lipodystrophy. AIDS 15 8 (2001) 975-982
40. Anastos K., Lu D., Shi O., et al. The association of bone mineral density with HIV infection and antiretroviral treatment in women. Antivir Ther 12 7 (2007) 1049-1058
41. Brown T.T., Ruppe M.D., Kassner R., et al. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia. J Clin Endocrinol Metab 89 3 (2004) 1200-1206